If a plan denies coverage citing that GLP-1s arent covered for obesity, families can appeal under EPSDT, the plan must evaluate medical necessity rather than blanket-deny based on drug category
Rushing the dose escalation is one of the most common mistakes new users make
Idris, I., Abdulla, H., Tilbrook, S., Dean, R
A brief on how retatrutide works Retatrutide is an investigational once-weekly injectable that activates three hormone receptor systems at once, GLP-1, GIP, and glucagon, which slows digestion, improves insulin response, and directly promotes fat burning
The small studies on knee pain and bladder pain are interesting, but they involved fewer than 30 patients total
Noonly the abdomen, outer thigh, and back of the upper arm have been approved for semaglutide injection